Platelet Function Disorders Program
Our innovative approach
The Dana-Farber/Children's Hospital Cancer Center Platelet Function Disorders Program is a world leader in ITP research, and we are currently conducting a number of studies in order to improve the diagnosis and treatment of ITP and other platelet disorders.
The primary purpose of this study is to learn about the safety of a drug called rituximab and how well it works in children and adolescents with chronic, severe ITP. Ten medical centers in the United States are participating in this trial, based here and directed by Ellis Neufeld, MD, PhD.
North American ITP registry
Our Platelet Function Disorders Program has formed a North American database to help understand the long-term outcome of children and adolescents with ITP. Once this information is analyzed, it may lead to a better understanding of chronic ITP in North America and improve the way specialists care for their young patients with this chronic disease.
International splenectomy registry
Researchers are collecting information, internationally, regarding splenectomy in young persons with ITP. This study may lead to the better understanding of the effects of splenectomy on children and young adults with ITP.
International childhood ITP registry
We participate in a large international study to help better define the long-term course in children newly diagnosed with ITP. Once this information is carefully analyzed, it may lead to the development of new treatment guidelines that will improve the care of children with ITP.
Study of treatment side effects
This is a multi-center study to evaluate the side effects of the various treatments of ITP. The study involves a survey to help gather information about side effects of ITP management plans.